MAI Capital Management’s BioAge Labs BIOA Stock Holding History

MAI Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	-$105	–	4841
2026 Q1	$105	Buy	+6	New	+$116	﹤0.01%	4751

Other funds holding BIOA

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

MAI Capital Management's BIOA Position: Q2 2026 in Review

MAI Capital Management sold out of BioAge Labs (BIOA) in Q2 2026, closing a stake of 6 shares — an estimated $105 sold.

MAI Capital Management first reported a position in BIOA in Q1 2026 and held it in 1 quarter. The position peaked at $105 in Q1 2026. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

MAI Capital Management reported no remaining BioAge Labs position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 6 BioAge Labs shares in Q2 2026, an estimated $105.
MAI Capital Management first reported a position in BioAge Labs in Q1 2026 and held it in 1 quarter.
MAI Capital Management's BioAge Labs position peaked at $105 in Q1 2026.
151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.